Global HIV Vaccine Enterprise

A safe and effective HIV vaccine is central to efforts to slow and ultimately end the AIDS epidemic. Developing such a vaccine is also among the greatest scientific challenges ever undertaken, one that requires the collaborative efforts of the world’s best researchers and scientific organizations. Real progress has been made and much has been learned, and while there is great optimism in the research community, many more years of hard work lie ahead.

Created in 2005, the Global HIV Vaccine Enterprise (Enterprise) is a unique alliance of global leaders in HIV vaccine research, funding, and advocacy. The Enterprise works to accelerate a coordinated, collaborative program of independent research intended to produce safe and effective HIV vaccines. It identifies gaps and emerging needs that must be addressed, working with partners to develop solutions. In this role, the Enterprise plays a critical convening role for the scientific and donor communities. 

Key partners in the Enterprise alliance include the ANRS: France Recherche Nord & Sud Sida-HIV Hépatites (ANRS FRENSH), AVAC: Global Advocacy for HIV Prevention, the Bill & Melinda Gates Foundation, GlaxoSmithKline Vaccines (GSK), International AIDS Vaccine Initiative (IAVI), U.S. Military HIV Research Program (MHRP), and the U.S. National Institutes of Allergy and Infectious Diseases (NIAID).

A small Enterprise secretariat, based in New York City, facilitates the Enterprise efforts to promote coordination, collaboration, knowledge sharing and the optimization of resources in the field. For further information visit vaccineenterprise.org.